Pipermethystine

Pipermethystine at a Glance

Pipermethystine is a piperidine alkaloid (a pyridone / N-acyl piperidinone) found in kava (Piper methysticum). Unlike the kavalactones that carry kava’s calming activity and sit in the root, pipermethystine is confined to the aerial parts — the leaves and stem peelings — and is essentially absent from the peeled root used to make the traditional beverage ^{2,4Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →}.

Its significance is almost entirely a safety one. In cultured human liver cells, pipermethystine is markedly cytotoxic: it collapses mitochondrial function and triggers programmed cell death at concentrations where the kavalactones do nothing ^{1Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}. That finding made it a leading suspect in the rare cases of liver injury that led several countries to restrict kava products in the early 2000s — and it put a spotlight on which part of the plant those products were made from ^{1,5Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}.

The honest headline is that the case against pipermethystine is strong in a test tube and weak in a living animal. It is a genuine in-vitro hepatotoxin, but the one short rodent feeding study did not reproduce overt liver injury, and analytical work found the alkaloid missing from the commercial Western extracts implicated in the case reports ^{3,4,5Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}. So pipermethystine is best read as a plausible contributor tied to aerial-part sourcing, not a proven cause — and as the clearest argument for keeping kava a root-only product.

Root vs. Aerial Parts: The Crux Of The Kava Liver Debate

The single most useful thing to know about pipermethystine is where it lives in the plant, because that is what connects it to the kava-safety controversy.

Pacific Islanders have prepared kava for centuries from the peeled underground parts — the rootstock and rhizome — as a water-based beverage, with a long record of apparent safety ^{5Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}. The molecules responsible for kava’s effects, the six major kavalactones, are concentrated there. Pipermethystine is not: chemical surveys locate it in the leaves and stem peelings, the aerial tissues that traditional preparation discards ^{2,4Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →}.

The problem arose when demand outran root supply. To stretch raw material, some manufacturers used stem peelings and other aerial parts as a cheaper kavalactone source ^{2Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →}. That practice imports the aerial-part alkaloid into a product that traditional use never contained — the essence of the “wrong plant part” hypothesis for kava hepatotoxicity ^{1,5Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}.

Two facts make this the crux of the debate rather than a settled verdict:

• The concentration gap is real and large. Leaves carry pipermethystine at roughly 0.2% of dry weight, while it is undetectable in the peeled root and in properly made root extracts (below a ~45 ppm limit of quantification) ^{4Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →}.
• But the implicated Western products often did not contain it. When researchers actually assayed the ethanolic and acetonic extracts linked to European case reports, pipermethystine was not detectable — pointing either to well-sourced root material or to a different culprit entirely ^{4,5Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}.

So the molecule that best explains how aerial-part kava could injure the liver was frequently missing from the very products that did. That tension — a convincing in-vitro mechanism, an aerial-part exposure route, and inconsistent detection in the real cases — is why pipermethystine remains a leading candidate rather than the answer.

Toxicological Evidence

Pipermethystine has no therapeutic use, so the “evidence by application” below tracks toxicological claims, not benefits. The load-bearing caveat is the compound-page discipline: the strong data are in-vitro, on the isolated alkaloid, and the one in-vivo animal test and the analytical surveys pull the other way ^{1,3,4,5Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is a toxicological claim; scores are capped by the fact that the strong data are in-vitro isolate work with no human confirmation.

01In-Vitro Hepatocyte CytotoxicityPromising56%HepG2 viability loss at 50–100 µM; kavalactones inactive ^{1Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}

02Mitochondrial Disruption (Mechanism)Promising46%↓ATP, ↓membrane potential, caspase-3 apoptosis in HepG2 ^{1Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}

03CYP450 / Oxidative-Stress ModulationShaky38%Rat: ↑CYP2E1/1A2, ↑glutathione/SOD, ↑TNF-α mRNA ^{3Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →}

04In-Vivo HepatotoxicityShaky22%Rat feeding gave no overt liver injury; not detected in implicated extracts ^{3,4,5Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}

Mechanisms

The load-bearing point is the contrast: at concentrations where kavalactones are inert, pipermethystine specifically wrecks mitochondria — which is why the aerial-part alkaloid, not the root’s active constituents, became the toxicity suspect ^{1Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}.

Pharmacokinetics

Human pharmacokinetics of isolated pipermethystine are not characterised — there are no ADME, bioavailability or half-life data, because it is a plant liability that no one doses on purpose. The only in-vivo handling comes from the rat study, where 10 mg/kg oral pipermethystine for two weeks induced hepatic CYP2E1 and CYP1A2 without overt injury, implying the alkaloid is absorbed and metabolised by the liver and can perturb its own (and other substrates’) metabolism ^{3Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →}. Structurally, the molecule carries reactive features — an α,β-unsaturated lactam and, in the related cultivar alkaloid 3α,4α-epoxy-5β-pipermethystine, an epoxide — that make reactive-metabolite formation a plausible but unproven contributor to its cytotoxicity ^{2,6Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →Reference 6Olsen LR et al. · 2011ReviewConstituents in kava extracts potentially involved in hepatotoxicity: a reviewView study →}. The practical read: the in-vitro potency should be weighed against unknown human exposure and disposition, which is exactly the uncertainty that keeps this a candidate rather than a confirmed toxin.

Clinical Trials

There are, and should be, no clinical trials of pipermethystine — it is a toxicology subject, not a therapeutic. The human “evidence” is the epidemiological signal: a cluster of rare hepatotoxicity case reports associated with kava products in Western countries around 2000–2002, which prompted regulatory restrictions and the search for a culprit constituent ^{1,5Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}. Pipermethystine is one hypothesis within that investigation, alongside flavokavain B and mould-derived hepatotoxins ^{5,7,8Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →Reference 7Rowe A · 2012Are mould hepatotoxins responsible for kava hepatotoxicity? Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/22319018/View study →Reference 8Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule inverts the usual “the isolate is over-tested” caveat in an instructive way. All of pipermethystine’s toxicity data are the isolated alkaloid — the HepG2 cytotoxicity and mitochondrial mechanism ^{1Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}, and the rat feeding dose ^{3Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →} — which is a strength for attributing the effect to the molecule, but a weakness for translating it to a product. The whole-plant reality cuts against a simple story: the traditional beverage is made from root, where pipermethystine is essentially absent, and even the implicated Western extracts frequently contained none of it ^{4,5Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}. So the isolate is a demonstrable liver-cell toxin, but the exposure that matters — root beverage or root extract — largely does not deliver it. The transferability caveat runs backwards here: the danger the isolate shows is real, but the mainstream plant preparation does not carry the isolate.

Its Role In Plants

Pipermethystine is one of a small family of piperidine (2-pyridone / piperidinone) alkaloids produced in kava’s aerial tissues, alongside the related 3α,4α-epoxy-5β-pipermethystine (found only in some cultivars, such as cv. Isa) and awaine, which occurs chiefly in young leaves across cultivars ^{2Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →}. Their restriction to leaves and stem peelings — the parts most exposed to herbivores and pathogens — is consistent with a chemical-defence role for these alkaloids, the general function such nitrogen-containing secondary metabolites serve in plants, though the specific ecology has not been experimentally pinned down for pipermethystine. The full biosynthetic pathway in Piper methysticum is not well characterised.

Prevalence In Nature

Pipermethystine is, as far as the literature records, specific to Piper methysticum and to its aerial parts. Chemical surveys of eleven kava cultivars localised the alkaloid to the stem peelings and leaves, with the related epoxy alkaloid confined to a single cultivar and awaine concentrated in young leaves ^{2Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →}. Quantitatively, leaves carry pipermethystine at around 0.2% of dry weight, whereas it is not detectable in the peeled root or in properly prepared root extracts (below a ~45 ppm limit of quantification) ^{4Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →}. It has no reported occurrence outside kava, and no meaningful presence in the plant part used for the traditional drink — which is precisely why it functions as a marker of aerial-part adulteration rather than a widespread phytochemical.

Source	Plant part	Reported pipermethystine content
Kava (Piper methysticum)	leaves	~0.2% dry weight 4Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →
Kava (Piper methysticum)	stem peelings	concentrated (primary aerial reservoir; not quantified as %) 2Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →
Kava (Piper methysticum)	peeled root / rootstock	not detectable (< ~45 ppm) 4Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →

Discovery & Synthesis

Pipermethystine was first isolated from kava leaves in the late 1970s and re-characterised in full by Klaus Dragull, Wesley Yoshida and Chung-Shih Tang at the University of Hawaii in 2003, who isolated it — together with the new alkaloids 3α,4α-epoxy-5β-pipermethystine and awaine — from the aerial parts of Piper methysticum and confirmed the structures by high-resolution mass spectrometry and NMR ^{2Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →}. It was this Hawaii group that both localised the alkaloid to the leaves and stem peelings and, the following year, demonstrated its HepG2 cytotoxicity ^{1,2Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →}.

The molecule has attracted repeated attention from synthetic chemists, partly to settle its stereochemistry. Both enantiomers were first total-synthesised in 2001 by Arrayás and colleagues via a 5-hydroxy-dihydropyridone route ^{9Reference 9Arrayás RG et al. · 2001Facile enantiodivergent approach to 5-hydroxy-5,6-dihydro-2(1H)-pyridonesView study →}; a diastereoselective synthesis of the epoxy analogue later fixed its absolute configuration ^{10Reference 10Osorio-Nieto U et al. · 2017The direct and highly diastereoselective synthesis of 3,4-epoxy-2-piperidonesView study →}; and a transition-metal-free total synthesis in 2020 revised the assigned absolute configuration of pipermethystine itself ^{11Reference 11Vázquez-Amaya LY et al. · 2020Transition-Metal-Free Total Synthesis and Revision of the Absolute Configuration of PipermethystineView study →}. There is no commercial production — pipermethystine is prepared only in milligram quantities for research, and any real-world exposure comes from kava aerial-part material, not from manufacture.

Patents: not yet researched.

Toxicity & Safety

Pipermethystine carries a moderate flag. That reflects a genuine tension rather than an established hazard: it is an unambiguous in-vitro liver-cell toxin with a defined mitochondrial mechanism ^{1Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}, yet the limited in-vivo animal work did not reproduce overt injury ^{3Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →} and the alkaloid is absent from the root beverage and from many implicated products ^{4,5Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}. The flag is a sourcing caution — a reason to insist on root-only kava — far more than a statement that pipermethystine has been proven to poison people. It is not alarmist to say that leaf/stem kava is best avoided; it would be alarmist to say pipermethystine is a demonstrated cause of human liver failure.

Safety at a Glance

⚠️ Moderate toxicityLiver risk

• A sourcing marker, not a beverage constituent. Pipermethystine sits in kava’s leaves and stem peelings and is essentially absent from the peeled root used traditionally — so root-only kava is the way to avoid it ^{2,4Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →}.
• In-vitro liver-cell toxin. In human liver-cell culture it collapses mitochondrial function and kills cells at concentrations where the kavalactones are harmless ^{1Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}.
• In-vivo evidence is unproven. A short rat feeding study showed no overt liver injury, and the alkaloid was not detected in the Western extracts tied to the case reports — the human case against it is unsettled ^{3,4,5Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}.
• Possible drug-interaction flag. It induced CYP2E1 and CYP1A2 in rat liver, a plausible basis for altered metabolism of co-ingested drugs, though not demonstrated in humans ^{3Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →}.
• It is one of several suspects. Flavokavain B and mould-derived hepatotoxins (e.g. aflatoxins from poorly stored raw material) are competing or additional explanations for kava hepatotoxicity ^{5,7,8Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →Reference 7Rowe A · 2012Are mould hepatotoxins responsible for kava hepatotoxicity? Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/22319018/View study →Reference 8Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}.

The wider debate matters for reading this molecule. Reviews stress that liver injury has followed both traditional aqueous and Western ethanolic/acetonic kava, that pipermethystine was not detectable in the commercial extracts implicated, and that flavokawain B (another aerial-part-enriched constituent) and mould contamination are live alternative hypotheses ^{5,7,8Reference 5Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →Reference 7Rowe A · 2012Are mould hepatotoxins responsible for kava hepatotoxicity? Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/22319018/View study →Reference 8Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}. In one mouse model, the flavokavains — not the kavalactone dihydromethysticin — potentiated acetaminophen-induced liver injury, keeping the chalcones firmly in the frame alongside pipermethystine ^{8Reference 8Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}. The most defensible current position is that kava hepatotoxicity is rare, multifactorial and sourcing-dependent, with pipermethystine a credible aerial-part contributor rather than a sole cause.

Pregnancy, lactation and individual contraindications are decisions made on the kava herb and product pages, where intake is actually chosen — not on this molecule page. The finding to carry across is simply that meaningful pipermethystine exposure signals leaf/stem-derived kava, which should be avoided regardless.

Dosage

There is no dose for pipermethystine — it is a plant liability, not an ingredient, and no one takes it deliberately. The only numbers in the literature are research quantities: the in-vitro cytotoxicity appeared at 50–100 µM in HepG2 cells ^{1Reference 1Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}, and the rat study used 10 mg/kg/day orally for two weeks ^{3Reference 3Lim ST et al. · 2007AnimalEffects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 ratsView study →}. Neither translates to a human intake.

What matters for real exposure is plant part, not milligrams: traditional peeled-root kava (aqueous beverage) delivers essentially none of the alkaloid, whereas products made with leaves or stem peelings can carry it at around 0.2% of leaf dry weight ^{2,4Reference 2Dragull K et al. · 2003Piperidine alkaloids from Piper methysticumView study →Reference 4Lechtenberg M et al. · 2008Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/View study →}. The practical takeaway is a sourcing rule — prefer root-only, noble-cultivar kava — not a dosing figure. These are in-vitro concentrations and animal research doses, not a personal recommendation.

References

1. Nerurkar PV, Dragull K, Tang CS (2004). In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicological Sciences. https://pubmed.ncbi.nlm.nih.gov/14737001/
2. Dragull K, Yoshida WY, Tang CS (2003). Piperidine alkaloids from Piper methysticum. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/12711141/
3. Lim ST, Dragull K, Tang CS, Bittenbender HC, Efird JT, Nerurkar PV (2007). Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicological Sciences. https://pubmed.ncbi.nlm.nih.gov/17329236/
4. Lechtenberg M, Quandt B, Schmidt M, Nahrstedt A (2008). Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271308/
5. Teschke R, Qiu SX, Lebot V (2011). Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Digestive and Liver Disease. https://pubmed.ncbi.nlm.nih.gov/21377431/
6. Olsen LR, Grillo MP, Skonberg C (2011). Constituents in kava extracts potentially involved in hepatotoxicity: a review. Chemical Research in Toxicology. https://pubmed.ncbi.nlm.nih.gov/21506562/
7. Rowe A, Ramzan I (2012). Are mould hepatotoxins responsible for kava hepatotoxicity? Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/22319018/
8. Narayanapillai SC, Leitzman P, O’Sullivan MG, et al. (2014). Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. Chemical Research in Toxicology. https://pubmed.ncbi.nlm.nih.gov/25185080/
9. Arrayás RG, Alcudia A, Liebeskind LS (2001). Facile enantiodivergent approach to 5-hydroxy-5,6-dihydro-2(1H)-pyridones. First total synthesis of both enantiomers of pipermethystine. Organic Letters. https://pubmed.ncbi.nlm.nih.gov/11594839/
10. Osorio-Nieto U, Vázquez-Amaya LY, Höpfl H, et al. (2017). The direct and highly diastereoselective synthesis of 3,4-epoxy-2-piperidones. Application to the total synthesis and absolute configurational assignment of 3α,4α-epoxy-5β-pipermethystine. Organic & Biomolecular Chemistry. https://pubmed.ncbi.nlm.nih.gov/29192703/
11. Vázquez-Amaya LY, Quintero L, Rodrı Guez-Molina B, et al. (2020). Transition-Metal-Free Total Synthesis and Revision of the Absolute Configuration of Pipermethystine. The Journal of Organic Chemistry. https://pubmed.ncbi.nlm.nih.gov/31994875/

View all 11 references▾